AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 63 min read$NTRA

Chapman Steven Leonard sold $380K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,742 shares of Natera, Inc. (NTRA) at $218.28 ($0.38M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The main tradable element is sentiment/positioning around insider activity; there is no new company-specific fundamental information in the filing.

02

Market read

Traders may briefly reassess sentiment/technical positioning, but the 10b5-1 designation limits fundamental interpretation.

03

What to watch

The disclosure does not reveal intent beyond the pre-arranged plan; without accompanying buys, it’s hard to infer directional conviction.

Relevance 6/10Novelty 4/10Timing: After-hours/next-session read-through of an SEC Form 4 insider sale (filed 2026-06-05).

Background

This is an SEC Form 4 insider transaction for Natera, reporting an officer/director open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and president Chapman Steven Leonard sold $380.3K of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine insider transaction disclosure and explicitly notes a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Sector

Minimal; single-company insider sale without new operational/regulatory/clinical catalysts.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales can coincide with diversification or liquidity needs and may not reflect bearish expectations; the market may overreact to the headline.

Key entities

  • issuer
    Natera, Inc.

    US-listed company whose CEO/president reported an open-market share sale under a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and president who sold 1,742 shares at ~$218.28/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 14
$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

fool.com6 min
AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min